Adhering to the service tenet of "Integrity, Innovation, Harmony, and Win-win", We have established a complete one-stop procurement and comprehensive solution service system.
Powder Favipiravir API cas 259793-96-9 is a nucleoside antiviral drug, it is previously known as T-705, is a prodrug of a purine nucleotide, favipiravir ribofuranosyl-5'-triphosphate. The active agent inhibits the RNA polymerase, halting viral replication.
Product introduction：
Cas: 259793-96-9
Other names: T-705, avigan
MF: C5H4FN3O2
Molecular Weight: 157.1
Appearance: Light yellow to off white,crystalline powder
Solubility: Soluble in water,freely soluble in Methanol, Acetonitrile
Assay(HPLC): 98%-102%
Description: Powder Favipiravir API cas 259793-96-9 is a nucleoside antiviral drug, it is previously known as T-705, is a prodrug of a purine nucleotide, favipiravir ribofuranosyl-5'-triphosphate. The active agent inhibits the RNA polymerase, halting viral replication. It is one of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza.
Application: Anti-virus, Covid-19, influenza and Ebola. Powder Favipiravir API cas 259793-96-9 (T-705) is a synthetic prodrug, first discovered while assessing the antiviral activity of chemical agents active against the influenza virus in the chemical library of Toyoma chemicals. A lead compound, A/PR/8/34, later designated as T-1105, and its derivatives were found to have antiviral activities. Powder Favipiravir API cas 259793-96-9 is derived by chemical modification of the pyrazine moiety of T-1105. It has been approved in Japan for the management of emerging pandemic influenza infections in 2014.
Other chemical names: Pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo- (9CI), 6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carboxaMide, T 705; FAVIPIRAVIR;T-705;T705
Sign up for our latest news & articles. We won’t give you spam mails.
Note: We do not publish your email
